Dr Jonathan Sherlock MRCP

 

Clinical Lecturer in Rheumatology

School of Immunity and Infection

Jonathan Sherlock

Contact details

University of Birmingham Research Laboratories
University Hospital Birmingham
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

About

Jonathan Sherlock is Clinical Lecturer in Rheumatology and works on the role of inflammatory cytokines in spondyloarthropathy in the context of development of better therapeutics for these conditions.

Qualifications

  • Master of Arts, University of Oxford, 2009 
  • Membership of the Royal College of Physicians 2008 
  • Bachelor of Medicine and Surgery, University of Cambridge 2005 
  • Bachelor of Arts, University of Oxford, 2002

Biography

Jonathan studied pre-clinical medicine at the University of Oxford and clinical medicine at the University of Cambridge. Following qualification in 2005 he worked as a doctor in East Anglia before moving to Birmingham in 2007 to work with Professor Christopher Buckley as an Academic Clinical Fellow in Rheumatology.

Jonathan has a longstanding keen interest in inflammatory pathology and development of novel therapeutics for the treatment of such illnesses. For three years from 2009 he worked at Merck Research Laboratories, California, on the role of interleukin-23 in spondyloarthropathy. He returned to clinical rheumatology as a Clinical Lecturer in Birmingham in 2012.

Teaching

  • BMedSci teaching at the University of Birmingham
  • Medical student clinical teaching at City Hospital, Birmingham

Research

Jonathan Sherlock works on the role of inflammatory cytokines in spondyloarthropathy, particularly the role of interleukin(IL)-23. This work has demonstrated that these conditions are driven by IL-23 which acts upon IL-23 responsive cells resident in the canonical sites of pathology such as the entheseal insertions of tendons and ligaments to bone.

Other activities

  • Honorary Registrar in Rheumatology at University Hospital Birmingham and Sandwell and West Birmingham NHS Trust.

Publications

IL-23 induces spondyloarthropathy by acting on ROR-γt(+) CD3(+)CD4(-)CD8(-) entheseal resident T cells.
Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, Gorman DM, Bowman EP, McClanahan TK, Yearley JH, Eberl G, Buckley CD, Kastelein RA, Pierce RH, Laface DM, Cua DJ. Nature Medicine 2012 Jul 1;18(7):1069-76

Autoimmunity's collateral damage: Gut microbiota strikes 'back'. Cua DJ, Sherlock JP.
Nature Medicine 2011 Sep 7;17(9):1055-6

Evidence-based management of ANCA vasculitis. Carruthers D, Sherlock J.
Best Pract Res Clin Rheumatol. 2009 Jun;23(3):367-78

A distinct subset of podoplanin (gp38) expressing F4/80+ macrophages mediate phagocytosis and are induced following zymosan peritonitis.
Hou TZ, Bystrom J, Sherlock JP, Qureshi O, Parnell SM, Anderson G, Gilroy DW, Buckley CD.
FEBS Lett. 2010 Sep 24;584(18):3955-61

Myasthenia gravis: diagnosis delayed or missed Sherlock J, McGourty J, Brown J
Geriatric Medicine 2007 3:49-53

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.
Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD. Nature. 2003 Feb 13;421(6924):744-8

Red cell indices as predictors of iron depletion in blood donors. Alexander HD, Sherlock JP, Bharucha C.
Clin Lab Haematol. 2000 Oct;22(5):253-8

Back to top